News, Policy & Media

01Mar

NHSi Market Engagement work 2018

Summary of the ask –
Deadline 30 April 2018

NHSI, in conjunction with BIVDA, invite suppliers to highlight via a short written summary
“examples of innovation that they are supporting currently in the health sector, and share with us future possibilities that their innovations could provide pathology services in the UK”.

Prior to 30th April 2018 suppliers are requested to submit a summary of no more than 3 pages, avoiding marketing materials and where appropriate provide objective and verifiable data to support claims of efficiency.

A wider advertisement in the process will follow to capture interest from those suppliers other than those known to BIVDA.

Follow questions, requests for clarification may be made by NHSI.  It is anticipated that meetings and site visits may in isolated case be requested, but this will be limited due to resources.

The “learning” from this work will help inform future guidance for Networks. Nothing specific from your summaries will be referenced in the report.

This work is NOT related to any one procurement and therefore is not intended to prohibit any supplier participating.  A mutual NDA is available on request.  At the conclusion of the process NHSI will a summary of conclusions.

To participate in this NHSI Market Engagement work, please send in pdf format to both enquiries@bivda.co.uk and nhsi.pathservices@nhs.net

Related

The Government’s national testing study is due to be expanded with a rise in fortnightly testi...

Read More >

Six healthcare organisations have united to pen a letter to Prime Minister Boris Johnson’s off...

Read More >

An Imperial College-led study has found that the adoption of new technologies into the health and ca...

Read More >

BIVDA has launched the latest in its series of strategic papers, ‘The Digital Revolution&rsquo...

Read More >

The new Lighthouse Lab in Charnwood, Loughborough has begun operations, processing thousands of COVI...

Read More >

Public Health England has stated that it will not change its policy around rapid point-of-care antib...

Read More >